OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-04-05-accounts

Pages
Reference and Administrative Information
Trustees'
Report
2-4
Independent
examiner's
report
Statement
of Financial
Activities
Balance Sheet
Notes to the Financial Statements 8-14
Reference and Administrative Reference and Administrative Information
for the year ended 5April 2023
Charity Reference: 1003899
Trustees: Mark Greaves
Michael Tyler (Chairman)
Michael Constant
James Naylor
Adam Renton
Mark Braganza
Jon Pleat
Address: Plastic Surgery J Corridor
Stoke Mandeville Hospital
Mandeville
Road
Aylesbury
HP21 8AL
Independent Examiner: Wenn Townsend
30StGiles
Oxford
Oxfordshire
OX1 3LE
Solicitors: Horwood 8 James LLP
7Temple Square
Aylesbury
Bucking
ham shire
HP20 2QB
Bankers: HSBC Bank pic
2 Walton Road
Aylesbury
Bucking ham shire
HP21 7SS
Investment managers: M 8 G Charities
PO Box9038
Chelmsford
Essex
CM99 2XF

Restore - Burn and Wound Resear Restore - Burn and Wound Resear Restore - Burn and Wound Resear
Statement ofFinancial Activides
For the year ended 5 April 2023
Note Unrestricted Restricted Total
funds funds 2023
E E E
Income:
Voluntary
income
2,588 2,588
Activities for raising funds 60,296 60,296
Total income 2,588 60,296 62,884
Expenditure:-
Costs of raising
voluntary
income 5 1,295 1,295
Charitable
expenditure:
Burns Research 6 28,257 23,123 51,380
Totalexpenditure 29,552 23,123 52,675
Net (expenditure)flncome (26,964) 37,173 10,209
Net (expenditure)/income before gains on
investments (26,964) 37,173 10,209
Unrealised
gains/(losses)
Realised gains on disposal
on investments 9
9
(1,132)
(411)
(1,132)
(411)
(28,507) 37,173 8,666
Transfers
between
funds
(28,507) 37,173 8,666
Fund balance brought forward 87,966 61,153 149,119
Fund balance carried forward 59,459 98,326 157,785
Unrestricted Restricted Endowment Total
funds funds funds 2022
E E E
3,982 3,982
27,000 27,000
3,982 27,000 30,982
1,218 1,218
30,832 587 31,419
32,050 587 32,637
(28,068) 26,413 (1,655)
(28,068) 26,413 (1,655)
10,926 10,926
(28,068) 26,413 10,926 9,271
104,834 (104,834)
76,766 26,413 (93,908) 9,271
11,200 34,740 93,908 139,848
87,966 61,153 149,119

Note 2023 2022
Fixed assets
Investments
Tangible assets
9
10
71,791
2,157
103,333
2,876
Current assets 73,948 106,209
Debtors
HSBC —community
Barclays account
account 443
85,879
929
45,469
174
86,322 46,572
Current liabilities
Creditors 12 (2,485) (3,662)
Net current assets 83,837 42,910
Net assets 157,785 149,119
Funds
Expendabie
endowment
funds
Unrestricted
funds
General 13 59,459
Designated 13 87,966
Restricted funds 14 98,326 61,153
157,785 149,119

Voluntary income
Unrestricted Restricted Total Total
2023 2022
E
Donations and legacies 2,588 2,588 2,622
Sponsorship Income 60,296 60,296 1,360
2,588 60,296 62,884 3,982

Unrestricted Restricted Total Total
2023 2022
Medical Research Council 60296 60296 27000
60,296 60,296 27,000
5. Costs of raising funds
Unrestricted Restricted Total Total
2023 2022
E
Advertising and publicity 432 432 432
Support costs (note 7) 204 204 330
Fundraising
Office expenses 659 659 456
1,295 1,295 1,218
6. Charitable expenditure
Total Total
Unrestricted Restricted 2023 2022f
Fellows' salaries 22,967 22,967 579
Director of Research 22,000 22,000 24,000
Support costs (note 7) 2,354 6 2,360 3,572
Research, equipment and travel 150 150
Prizes awarded 800 800 500
Governance costs (note 7) 3,103 3,103 2,768
Sponsorship Refund
28,257 23,123 51,380 31,419

Costs ofgenerating Costs ofgenerating Charitable Governance Total Total
Funds expenditure 2023
E
2022
f
Depreciation 72 575 72 719 959
Treasurer
salary
100 800 100 1,000 1,841
Secretarial
salary and
expenses 32 260 33 325 500
Auditor's
remuneration
2,898 2,899 2,438
Insurance 635 635 617
Legal Fees 300
Bank charges 90 90 15
2,360 3,103 5,668 6,670

Investments
2023 2022
Investments
are stated at fair value and movements
are:
At 6 April 2022 103,333 92,407
Disposal Proceeds (29,999)
Gain on disposal (1,132)
Increase/(Decrease) in market value (411) 10,926
At 5 April 2023 71,791 103,333

10. Tangible fixed assets
Computer and
other equipment
Cost:
At 6 April 2022 and at 5 April 2023 84,470
Depreciation:
At 6 April 2022 81,594
Charge for year 719
At 5 April 2023 82,313
Net book value:
At 5 April 2023 2,157
At 5 April 2022 2,876
11. Debtors
2023f 2022
f.
Prepayments 443 929
443 929
12. Creditors
Audit and accountancy accrued 2,160 2,621
Other accruals 325 1,041
2,485 3,662

At Gain on At
6April 2022 Income Expenditure investment Transfer 5 April 2023
F
General
fund
Designated
funds
87,966 2,588 (29,553) (1,542) 87,966
(87,966)
59,459
Total unrestricted funds 87,966 2,588 (29,553) (1,542) 59,459
At Gain on At
6April 2021 Income
F
Expenditure
f
investment Transfer
F
5 April 2022
General
fund
3,982 (31,550) 27,568
Designated
funds
11,200 (500) 77,266 87,966
Total unrestricted funds 11,200 3,982 (32,050) 104,834 87,966

Restricted funds
BEST" Immunomodulation Medical
Current year project project equipment
F.
Totalf
Balance at 6 April 2022 13,296 47,835 22 61,153
Income 33,296 27,000 60,296
Expenditure (150) (22,967) (6) (23,123)
Balance at 5 April 2023 46,442 51,868 16 98,326
BEST* Immunomodulation Medical
Prior year project project equipment Total
F
Balance at 6 April 2021 13,296 21,414 30 34,740
Income 27,000 27,000
Expenditure (579) (8) (587)
Balance at 5 April 2022 13,296 47,835 22 61,153

Division of net assets between funds
Current year
Unrestricted Restricted
funds funds Total
Fixed assets
Tangible fixed assets 2,141 16 2,157
Investments 71,791 71,791
73,932 16 73,948
Debtors 443 443
Cash at bank and in hand (12,431) 98,310 85,879
Creditors (2,485) (2,485)
Net assets 59,459 98,326 157,585
Prior year
Unrestricted Restricted
funds funds Total
Fixed assets
Tangible fixed assets 2,854 22 2,876
Investments 103,333 103,333
106,187 22 106,209
Debtors 929 929
Cash at bank and in hand (15,488) 61,131 45,643
Creditors (3,662) (3,662)
Net assets 87,966 61,153 149,119